Multidisciplinary treatment for adult soft tissue sarcoma

被引:0
作者
Lordick, F. [1 ]
机构
[1] Univ Klinikum Heidelberg, Natl Ctr Tumorerkrankungen, D-69120 Heidelberg, Germany
来源
CHIRURG | 2009年 / 80卷 / 03期
关键词
Soft tissue sarcoma; Multidisciplinary; Radiotherapy; Chemotherapy; Adjuvant; PHASE-II TRIAL; RADIATION-THERAPY; CHEMOTHERAPY; FIBROMATOSIS; PACLITAXEL; IMATINIB; BONE; ECTEINASCIDIN-743; RECOMMENDATIONS; ANGIOSARCOMA;
D O I
10.1007/s00104-008-1597-4
中图分类号
R61 [外科手术学];
学科分类号
摘要
The current standard in local treatment of soft tissue sarcomas has shifted from amputation and similar mutilating resections to more organ- and function-preserving surgery. This was possible through multidisciplinary treatment approaches, particularly those including adjuvant radiation therapy. Adjuvant radiation showed significant improvement in local tumour control after resection with tight margins and in high-risk sarcomas. Unfortunately adjuvant radiation failed to improve overall survival. Perioperative chemotherapies also have not contributed to improvement in the overall prognosis worldwide. Progress may occur when the pathogenesis and molecular profile of specific sarcoma subtypes are better understood, allowing more effective new drugs. One example is the treatment of advanced gastrointestinal stromal tumour with imatinib, a small molecular kinase inhibitor of the c-kit receptor. Presently the most effective measure to improve the prognosis with soft tissue sarcomas is early patient referral to expert centres, where diagnostic workup and therapy decisions are made on a multidisciplinary basis and updated according to the newest guidelines and study results.
引用
收藏
页码:209 / 215
页数:7
相关论文
共 51 条
  • [1] *AJCC, 2002, AJCC CANC STAG HDB
  • [2] AN INTERGROUP PHASE-III RANDOMIZED STUDY OF DOXORUBICIN AND DACARBAZINE WITH OR WITHOUT IFOSFAMIDE AND MESNA IN ADVANCED SOFT-TISSUE AND BONE SARCOMAS
    ANTMAN, K
    CROWLEY, J
    BALCERZAK, SP
    RIVKIN, SE
    WEISS, GR
    ELIAS, A
    NATALE, RB
    COOPER, RM
    BARLOGIE, B
    TRUMP, DL
    DOROSHOW, JH
    AISNER, J
    PUGH, RP
    WEISS, RB
    COOPER, BA
    CLAMOND, GH
    BAKER, LH
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) : 1276 - 1285
  • [3] Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy
    Blay, JY
    van Glabbeke, M
    Verweij, J
    van Oosterom, AT
    Le Cesne, A
    Oosterhuis, JW
    Judson, I
    Nielsen, OS
    [J]. EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 64 - 69
  • [4] Limb salvage with isolated perfusion for soft tissue sarcoma:: could less TNF-α be better?
    Bonvalot, S
    Laplanche, A
    Lejeune, F
    Stoeckle, E
    Le Péchoux, C
    Vanel, D
    Terrier, P
    Lumbroso, J
    Ricard, M
    Antoni, G
    Cavalcanti, A
    Robert, C
    Lassau, N
    Blay, JY
    Le Cesne, A
    [J]. ANNALS OF ONCOLOGY, 2005, 16 (07) : 1061 - 1068
  • [5] Bramwell VH., 2003, COCHRANE DB SYST REV, V3, pCD003293, DOI DOI 10.1002/14651858.CD003293
  • [6] Soft tissue sarcomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Casali, P. G.
    Jost, L.
    Sleijfer, S.
    Verweij, J.
    Blay, J. -Y.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 89 - 93
  • [7] Medical progress: Soft-tissue sarcomas in adults
    Clark, MA
    Fisher, C
    Judson, I
    Thomas, JM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (07) : 701 - 711
  • [8] A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma - A study by the Spanish group for research on sarcomas
    del Muro, XG
    Lopez-Pousa, A
    Martin, J
    Buesa, JM
    Martinez-Trufero, J
    Casado, A
    Poveda, A
    Cruz, J
    Bover, I
    Maurel, J
    [J]. CANCER, 2005, 104 (08) : 1706 - 1712
  • [9] Current uses of isolated limb perfusion in the clinic and a model system for new strategies
    Eggermont, AMM
    de Wilt, JHW
    ten Hagen, TLM
    [J]. LANCET ONCOLOGY, 2003, 4 (07) : 429 - 437
  • [10] Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.3.CO